AVA-001 / Avalon GloboCare, BriSTAR Immunotech - LARVOL DELTA

HXYT-002: CD19-CAR-T in B-cell Malignancies Patients (clinicaltrials.gov) - P1 | N=11 | Completed | Sponsor: Hebei Yanda Ludaopei Hospital | Recruiting ➔ Completed | N=20 ➔ 11 | Trial completion date: Oct 2021 ➔ Mar 2021

Enrollment change • Trial completion • Trial completion date • Hematological Malignancies • Oncology • CD19

Avalon GloboCare Provides Clinical Updates on Its CAR-T Immuno-Oncology and Allogeneic Mesenchymal Stromal Cell (MSC) Therapy Programs Following Successful Completion of Phase I AVA-001 Clinical Trial (Avalon GloboCare Corp Press Release) - P1, N=20; NCT03952923; "Avalon GloboCare Corp...provided a clinical update on its chimeric antigen receptor (CAR) T-cell therapy and allogeneic mesenchymal stromal cell (MSC) therapy programs following successful completion of its Phase I clinical trial of AVA-001...Ninety percent of R/R B-ALL patients on trial achieved complete remission within one month of AVA-001 treatment and successfully proceeded to a curative-intent allogeneic bone marrow transplant....Avalon is expanding its AVA-001 clinical trial to recruit patients with relapsed/refractory Non-Hodgkin lymphoma (R/R-NHL)."

P1 data • Trial status • Acute Lymphocytic Leukemia • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology

Avalon GloboCare Provides Updates on its Lead Scientific and Clinical Programs in CAR T-Cell Therapy and COVID-19 (Avalon GloboCare Corp Press Release) - P1, N=20; NCT03952923; "Avalon has successfully completed a Phase I first-in-human clinical study of its leading CAR T-cell therapy candidate, AVA-001...Nine out of ten patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) have achieved complete remission (CR rate of 90%) within one month after receiving one dose of AVA-001 CAR T-cell therapy. The treatment with AVA-001 was generally well tolerated with minimal adverse side effects: no neurotoxicity or greater than Grade-1 cytokine release syndrome was observed in this cohort of patients treated with AVA-001....Avalon expects to begin a first-in-human clinical trial with AVA-011 for the treatment of relapsed/refractory B-cell lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma in the first quarter of 2021."

New trial • P1 data • Trial status • Acute Lymphocytic Leukemia • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology

Avalon GloboCare Announces Successful Completion of Phase I Clinical Study of CAR T-Cell Therapy Candidate AVA-001 (Avalon GloboCare Corp Press Release) - P1, N=20; NCT03952923; "Avalon GloboCare Corp...announced today it has successfully completed Phase I first-in-human clinical study of its leading Chimeric Antigen Receptor (CAR) T-cell therapy candidate, AVA-001....Nine out of ten patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) have achieved complete remission (CR rate of 90%) within one month after the initiation of AVA-001 CAR T-cell therapy treatment. The treatment with AVA-001 was generally well tolerated with minimal toxicities and adverse side effects. No neurotoxicity or greater than Grade-1 cytokine release syndrome was observed in this cohort of patients treated with AVA-001."

Cytokine release syndrome • P1 data • Trial status • Acute Lymphocytic Leukemia • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology

Avalon GloboCare Announces Initiation of First-in-Human Clinical Trial of its CAR-T Candidate, AVA-001, for Treatment of B-Cell Malignancies (GlobeNewswire, Avalon GloboCare Corp.) - "FREEHOLD, N.J., Sept 19, 2019 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, today announced it has initiated its first-in-human, Phase I clinical trial of CD19 Chimeric Antigen Receptor (CAR)-T candidate, AVA-001, at the Hebei Yanda Lu Daopei Hospital and Beijing Lu Daopei Hospital in China. AVA-001 was designed to provide a more powerful, personalized CAR delivery mechanism."

Enrollment status

Newly added product (GlobeNewswire) - P1, Hematological Malignancies, Non-Hodgkin’s Lymphoma

Pipeline update